DrugPatentWatch Database Preview
KERYDIN Drug Profile
When do Kerydin patents expire, and when can generic versions of Kerydin launch?
Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-nine patent family members in twenty countries.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tavaborole profile page.
Summary for KERYDIN
| International Patents: | 69 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 59 |
| Clinical Trials: | 1 |
| Patent Applications: | 57 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for KERYDIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KERYDIN |
| DailyMed Link: | KERYDIN at DailyMed |
Generic Entry Opportunity Date for KERYDIN
Generic Entry Date for KERYDIN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KERYDIN
| Drug Class | Oxaborole Antifungal |
| Mechanism of Action | Protein Synthesis Inhibitors |
Synonyms for KERYDIN
| 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole |
| 174671-46-6 |
| 2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy- |
| 3338AH |
| 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole |
| 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole |
| 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol |
| 5-fluoro-2,1-benzoxaborol-1(3H)-ol |
| 5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol |
| 5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol |
| 5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL |
| AK163946 |
| AKOS006303927 |
| AN 2690 |
| AN-2690 |
| AN-2690(Tavaborole) |
| AN-2690) |
| AN2690 |
| BDBM50370987 |
| C7H6BFO2 |
| CHEBI:77942 |
| CHEMBL443052 |
| CS-1058 |
| CTK8H2675 |
| D05VGL |
| D10169 |
| DB09041 |
| DTXSID00169888 |
| EX-A1086 |
| FT-0697827 |
| Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough |
| Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor |
| HSDB 8342 |
| HY-10980 |
| K124A4EUQ3 |
| KB-74687 |
| Kerydin (TN) |
| KS-00000SPV |
| LFQDNHWZDQTITF-UHFFFAOYSA-N |
| MB08883 |
| MFCD10699483 |
| MolPort-027-845-281 |
| NCGC00264110-01 |
| SCH-900340 |
| SCHEMBL500016 |
| ST24044751 |
| Tavaborole |
| Tavaborole (USAN) |
| Tavaborole [USAN:INN] |
| Topical antifungal (onychomycosis), Merck & Co |
| Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough |
| Trichophyton-targeting antifungal (onychomycosis), Merck & Co |
| UNII-K124A4EUQ3 |
| W-5454 |
| X3699 |
| Z1739256284 |
| ZINC169990691 |
US Patents and Regulatory Information for KERYDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for KERYDIN
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 5% | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for KERYDIN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 101456815 | ➤ Try a Free Trial |
| South Korea | 101337045 | ➤ Try a Free Trial |
| Russian Federation | 2010133524 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
